NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Pre-Mkt 04-23 09:00:29 EDT

16.98

+0.61

+3.73%

盘前17.00

+0.02+0.12%

07:22 EDT

High17.47	Low16.49	Vol253.53K
Open16.49	D1 Closing16.37	Amplitude5.99%
Mkt Cap571.66M	Tradable Cap389.06M	Total Shares33.67M
T/O4.33M	T/O Rate1.11%	Tradable Shares22.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":16.98,"timestamp":1776888000000,"preClose":16.37,"halted":0,"volume":253525,"hourTrading":{"tag":"盘前","latestPrice":17,"preClose":16.98,"latestTime":"07:22 EDT","volume":1,"amount":17,"timestamp":1776943325685,"change":0.02,"changeRate":0.001178,"amplitude":0},"delay":0,"changeRate":0.03726328649969453,"floatShares":22912800,"shares":33666948,"eps":-0.655971,"marketStatus":"Pre-Mkt","change":0.61,"latestTime":"04-23 09:00:29 EDT","open":16.49,"high":17.47,"low":16.49,"amount":4329758.225528,"amplitude":0.059866,"askPrice":17.5,"askSize":10,"bidPrice":13.65,"bidSize":146,"shortable":3,"etf":0,"ttmEps":-0.655971,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776951000000},"marketStatusCode":1,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":16.98,"preHourTrading":{"tag":"盘前","latestPrice":17,"preClose":16.98,"latestTime":"07:22 EDT","volume":1,"amount":17,"timestamp":1776943325685,"change":0.02,"changeRate":0.001178,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":16.98,"preClose":16.98,"latestTime":"16:19 EDT","volume":1028,"amount":17454.94,"timestamp":1776889178614,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.1395295464729993,"impliedVol":0.7359,"impliedVolPercentile":0.64},"requestUrl":"/m/hq/s/NPCE/tweets","defaultTab":"tweets","newsList":[{"id":"2629905773","title":"NeuroPace announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629905773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629905773?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:07","pubTimestamp":1776802025,"startTime":"0","endTime":"0","summary":"NeuroPace scheduled annual shareholder meeting for June 5, 2026 in virtual format.Shareholders will vote on election of Lisa Andrade, Scott Huennekens as Class II directors with terms running to 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL9pV4RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110422","title":"NeuroPace to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110422","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110422?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:05","pubTimestamp":1775851520,"startTime":"0","endTime":"0","summary":"NeuroPace management to present at 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 1:30 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDLc5xX5V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624452805","title":"NeuroPace Earnings Call Highlights Growth And AI Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2624452805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624452805?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:21","pubTimestamp":1775089306,"startTime":"0","endTime":"0","summary":"Neuropace, Inc. (($NPCE)) has held its Q4 earnings call. Read on for the main highlights of the call. NeuroPace’s latest earnings call struck an up...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-highlights-growth-and-ai-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-highlights-growth-and-ai-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIPO","AGIX","CHAT","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620210252","title":"Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620210252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620210252?lang=en_us&edition=fundamental","pubTime":"2026-03-18 22:30","pubTimestamp":1773844226,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kestra Medical Technologies Ltd. (KMTS – Research Re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-kestra-medical-technologies-ltd-kmts-neuropace-npce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-kestra-medical-technologies-ltd-kmts-neuropace-npce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE","BK4539","XBI","BK4588","BK4112","BLSG","BK4137","BK4581","LU0128526141.USD","KMTS","LABU","BK4082","BK4585","LU0029874061.USD","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620523291","title":"NeuroPace assumed with an Overweight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2620523291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620523291?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:25","pubTimestamp":1773829519,"startTime":"0","endTime":"0","summary":"Wells Fargo assumed coverage of NeuroPace (NPCE) with an Overweight rating and $19 price target The firm is maintaining the current rating, price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-assumed-with-an-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-assumed-with-an-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579558","title":"NeuroPace to Present at Leerink 2026 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579558","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579558?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:30","pubTimestamp":1772746221,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL5L23sd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617182275","title":"Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2617182275","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617182275?lang=en_us&edition=fundamental","pubTime":"2026-03-05 14:00","pubTimestamp":1772690423,"startTime":"0","endTime":"0","summary":"Neuropace, Inc. (NPCE) has disclosed a new risk, in the Taxation & Government Incentives category. Neuropace, Inc. faces heightened regulatory timi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-shutdowns-threaten-neuropaces-fda-approvals-and-capital-market-access?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-shutdowns-threaten-neuropaces-fda-approvals-and-capital-market-access?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617596715","title":"NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2617596715","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617596715?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:31","pubTimestamp":1772677864,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE) has just closed out FY 2025 with Q4 revenue of US$26.6 million and a basic EPS loss of US$0.08, while trailing twelve month figures show revenue of US$100.0 million and a basic EPS loss of US$0.66 as the company continues to operate at a loss. Over the past several quarters, the business has seen revenue move from US$21.5 million in Q4 2024 to US$26.6 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.18 and US$0.26 before the latest US$0.08 print. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-npce/neuropace/news/neuropace-npce-loss-narrowing-in-q4-tests-bullish-profitabil","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-npce/neuropace/news/neuropace-npce-loss-narrowing-in-q4-tests-bullish-profitabil","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","NPCE","BK4082","BK4539","BLSX","BLSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617561730","title":"Neuropace Chief Medical Officer Martha Morrell Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617561730","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617561730?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:44","pubTimestamp":1772660644,"startTime":"0","endTime":"0","summary":"Martha Morrell, Chief Medical Officer of NeuroPace Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL69CNzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neuropace Chief Medical Officer Martha Morrell Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616237208","title":"NeuroPace forecasts 2026 revenue of $98 million to $100 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616237208","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616237208?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:03","pubTimestamp":1772575420,"startTime":"0","endTime":"0","summary":"NeuroPace forecast 2026 revenue of $98 million to $100 million, following 2025 revenue of $100 million, up 25% year over year. The company also expects RNS revenue growth of about 20% to 22% in 2026, after RNS revenue rose 25% to $81.7 million in 2025. For 2026, NeuroPace guided to non-GAAP operating expenses of $90 million to $92 million, non-GAAP gross margin of 81.5% to 82.5%, and adjusted EBITDA of a $9 million to $10 million loss.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL73pFyz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616137466","title":"NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M","url":"https://stock-news.laohu8.com/highlight/detail?id=2616137466","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616137466?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:19","pubTimestamp":1772572770,"startTime":"0","endTime":"0","summary":"16:12 EST NeuroPace (NPCE) sees Q1 revenue $21M-$22M, consensus $21.93M Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-sees-q1-revenue-21m-22m-consensus-21-93m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-sees-q1-revenue-21m-22m-consensus-21-93m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616371781","title":"NeuroPace Q4 EPS $(0.08) Beats $(0.17) Estimate, Sales $26.588M Beat $24.791M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371781","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371781?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:07","pubTimestamp":1772572054,"startTime":"0","endTime":"0","summary":"NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52.66 percent. This is a 55.56 percent increase over losses of $(0.18) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51018442/neuropace-q4-eps-0-08-beats-0-17-estimate-sales-26-588m-beat-24-791m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeuroPace Q4 EPS $(0.08) Beats $(0.17) Estimate, Sales $26.588M Beat $24.791M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616371259","title":"BRIEF-NeuroPace, Inc. Q4 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371259","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371259?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:05","pubTimestamp":1772571947,"startTime":"0","endTime":"0","summary":"Mar 03  - NeuroPace, Inc. Q4 gross profit USD 20.578 million.Q4 revenue USD 26.588 million vs. IBES estimate USD 24.8 million. outlook FY revenue USD 98-100 million vs. IBES estimate USD 98.9 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX6F9D93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616711203","title":"Neuropace, Inc. Q4 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2616711203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616711203?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:05","pubTimestamp":1772571902,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX6F9D93:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616374730","title":"Neuropace Inc - Q1 2026 Revenue Guidance $21 Mln-$22 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374730?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:05","pubTimestamp":1772571902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX6F9D93:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616712613","title":"Press Release: NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2616712613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616712613?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:05","pubTimestamp":1772571900,"startTime":"0","endTime":"0","summary":"-- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth --. -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy  --. -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement  approval in mid-2026 --. NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.--  Total revenue of $26.6 million, representing growth of 24% compared to. --  RNS System revenue of $22.4 million, representing growth of 26%. --  Total gross margin of 77.4%, a 200-basis point increase compared to the. fourth quarter of 2024, driven by positive product mix and manufacturing. efficiencies. RNS gross margin in the fourth quarter of 2025 was of 80.5%,a 40 basi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4519","BK4232","IE00B19Z3B42.SGD","BK4585","BK4211","LU1093756168.USD","LU1093756325.SGD","BK4099","IE00B19Z3581.USD","BK4082","IE0002270589.USD","LU0061475181.USD","IGE","AES","BK4022","BK4195","TM","BK4588","BK4105","BK4539","BK4604","R","BK4555","PFS","IE00B7SZLL34.SGD","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616832598","title":"NeuroPace (NPCE) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2616832598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616832598?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:56","pubTimestamp":1772546189,"startTime":"0","endTime":"0","summary":"In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on NeuroPace, with a price target of $20.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neuropace-npce-receives-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neuropace-npce-receives-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616083333","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2616083333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616083333?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:00","pubTimestamp":1772449200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Crawford & Co                                  4Q       .23   4:15 PM. ·Credo Tech Hldg                                 3Q       .91   4:05 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","AAON","CRD.B","ACHR","ASTH","BRCB","ASAN","ADT","CRCT","DAVE","DDD","EOLS","ACEL","BOX","AMRC","CGEN","STNE","ALLO","ALG","FSTR","CRC","CERS","CRD.A","BGS","AMLX","EVGO","ANF","HCAT","ANTA","LIF","AFCG","ARCT","BEEP","BCYC","CVEO","GAIA","GTLB","AZO","ACR","BBY","ATRA","CORZ","CYRX","BLTE","CXDO","AEO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614576860","title":"Neuropace Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614576860","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614576860?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:59","pubTimestamp":1772229544,"startTime":"0","endTime":"0","summary":"Neuropace Inc  expected to post a loss of15cents a share - Earnings Preview Neuropace Inc NPCE.OQ NPCE.O is expected to  show a rise in quarterly revenue when it reports  results on March 3 for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN2UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614832984","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832984?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:00","pubTimestamp":1772190000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Arbor Realty Tr                                  4Q       .13   8:30 AM. ·Delek US Hldgs                                    4Q      (.19)  7:00 AM. ·NW Natural Hldg                                  4Q      1.36   6:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEN","CRI","BTSG","CRD.A","ADT","ASAN","AMRX","BBY","GSAT","AMRC","AZO","ACRS","CVEO","STNE","CERS","AMWD","ASTH","CLMT","BRK.A","CORZ","CRC","ATRA","ALXO","CRCT","CRD.B","BEEP","BRK.B","AMR","CXDO","LIF","ABR","BCYC","AMLX","ACEL","BGS","BOX","ACHR","AAON","ANTA","BLTE","BRCB","ANIP","ARCT","NPCE","ALG","CMPX"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.neuropace.com;investors.neuropace.com","stockEarnings":[{"period":"1week","weight":0.0878},{"period":"1month","weight":0.2691},{"period":"3month","weight":-0.0035},{"period":"6month","weight":0.6202},{"period":"1year","weight":0.5521},{"period":"ytd","weight":0.0997}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.0852},{"period":"3month","weight":0.0323},{"period":"6month","weight":0.0501},{"period":"1year","weight":0.3489},{"period":"ytd","weight":0.043}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.513635},{"month":2,"riseRate":0.4,"avgChangeRate":0.014939},{"month":3,"riseRate":0.2,"avgChangeRate":-0.075134},{"month":4,"riseRate":0.4,"avgChangeRate":0.056681},{"month":5,"riseRate":0.2,"avgChangeRate":-0.144641},{"month":6,"riseRate":0.6,"avgChangeRate":-0.044447},{"month":7,"riseRate":0.4,"avgChangeRate":-0.04203},{"month":8,"riseRate":0.6,"avgChangeRate":0.216975},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065676},{"month":10,"riseRate":0,"avgChangeRate":-0.132059},{"month":11,"riseRate":0.6,"avgChangeRate":0.163487},{"month":12,"riseRate":0.6,"avgChangeRate":0.015944}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction